Prognostic value of microRNA-126 and CRK expression in gastric cancer

Shun Yue1,*
Huichang Shi2,*
Jun Han3
Tiecheng Zhang1
Weiguo Zhu1
Dahong Zhang1

1Department of Medical Oncology, Huaian First People’s Hospital, Nanjing Medical University, Huaian City, 2Department of Medical Oncology, The Second People’s Hospital of Huaian, Huaian City, 3Department of Medical Oncology, Qinghai Province People’s Hospital, Xining City, People’s Republic of China

*These authors contributed equally to this work

Background: MicroRNA (miR)-126, acting as a tumor suppressor, has been reported to inhibit the invasion of gastric cancer cells in part by targeting v-crk sarcoma virus CT10 oncogene homologue (CRK). The aim of this study was to investigate the clinical significance of miR-126/CRK axis in gastric cancer.

Methods: miR-126 and CRK mRNA expression levels were detected by real-time quantitative reverse transcription polymerase chain reaction in 220 self-pairs of gastric cancer and adjacent noncancerous tissues.

Results: Expression levels of miR-126 and CRK mRNA in gastric cancer tissues were, respectively, lower and higher than those in adjacent noncancerous tissues (both \( P<0.001 \)). Low miR-126 expression and high CRK expression, alone or in combination, were all significantly associated with positive lymph node and distant metastases and advanced TNM stage of human gastric cancer (all \( P<0.05 \)). We also found that the overall survival rates of the patients with low miR-126 expression and high CRK expression were, respectively, shorter than those with high miR-126 expression and low CRK expression. Interestingly, miR-126-low/CRK-high expression was associated with a significantly worse overall survival of all miR-126/CRK groups (\( P<0.001 \)). Moreover, multivariate analysis identified miR-126 and/or CRK expression as independent prognostic factors for patients with gastric cancer. Notably, the prognostic relevance of miR-126 and/or CRK expression was more obvious in the subgroup of patients with TNM stage IV.

Conclusion: Dysregulation of miR-126/CRK axis may promote the malignant progression of human gastric cancer. miR-126 and CRK combined expression may serve as an independent predictor of overall survival in patients with advanced gastric cancer.

Keywords: miR-126, v-crk sarcoma virus CT10 oncogene homologue, prognosis, real-time quantitative polymerase chain reaction

Introduction

Gastric cancer ranks fourth in incidence (after lung cancer, breast cancer, and colorectal cancer) and second in mortality (after lung cancer) among all cancers in the world.1,2 In the People’s Republic of China, gastric cancer constitutes approximately 33% of all worldwide cases of this disease.3,4 The recent development of diagnostic and surgical techniques has greatly improved the prognosis of gastric cancer patients. However, approximately two-thirds of patients have locally advanced or metastatic disease at diagnosis, and up to one-half of patients have recurrent disease after curative surgery.5–7 Thus, it is extremely necessary to have a better understanding of gastric carcinogenesis and identify novel and efficient prognostic and/or therapeutic tumor markers to improve current management and assist in the earlier diagnosis of gastric cancer.

MicroRNAs (miRNAs), a class of noncoding small molecular single-chain RNAs including 18–25 nucleotides, have highly conservative, temporal, and tissue-specific...
characteristics. They carry out various biological functions by repressing the expression of their target genes at the posttranslational level through base-pairing with endogenous mRNAs. Growing evidence shows that numerous miRNAs are aberrantly expressed in various human cancer types, and miRNA expression profiling has shown certain miRNAs to be associated with cancer development, progression, and response to therapy. Accumulating studies suggest that miRNAs have a close relationship with gastric carcinogenesis. miR-126 originates from a common precursor structure located at chromosome 9q34.3, the seventh intron of the epidermal growth factor-like domain 7 (EGFL7) gene. Its expression is regulated by EGFL7 gene promoter and is generated by EGFL7 pre-mRNA splicing. Growing evidence shows that miR-126 is frequently downregulated in a variety of malignancies and functions as a potential tumor suppressor. In gastric cancer, Feng et al in 2010 reported that miR-126 was significantly downregulated and its overexpression in SGC-7901 cells potently inhibited cell growth by inducing cell cycle arrest in G0/G1 phase, migration, and invasion in vitro as well as tumorigenicity and metastasis in vivo. They also identified the adaptor protein v-crk sarcoma virus CT10 oncogene homologue (CRK) as a target of miR-126. Otsubo et al in 2011 indicated that exogenous miR-126 overexpression could significantly enhance the anchorage-dependent and -independent growth of gastric cancer cell lines. Wang et al in 2013 revealed that miR-126 could negatively regulate CRKL mRNA which promoted cell proliferation in gastric cancer. Liu et al in 2014 found that miR-126 could suppress growth of SGC-7901 cells by synergistically targeting the oncopgenes PI3KR2 and CRK and the tumor suppressor PLK2. In the same year, Li et al further revealed that overexpression of miR-126 inhibited gastric cancer cell invasion in part by targeting CRK. These findings suggest that miR-126/CRK axis may play an important role in gastric carcinogenesis. The aim of this study was to investigate the clinical significance of miR-126/CRK axis in human gastric cancer.

Materials and methods
The strategy of this study is shown in Figure 1. For real-time quantitative reverse transcription polymerase chain reaction (PCR), 220 patients (160 men, 60 women; median age, 60.0 years; range, 29–88 years) were recruited from the Department of Oncology, First Hospital of Huai’an, Nanjing Medical University between January 2000 and January 2006. All underwent total gastrectomy. Fresh samples of tumor tissues and matched normal gastric mucosa were obtained immediately after gastric resection. Resected specimens were studied pathologically according to the criteria described in the Union for International Cancer Control (UICC) pTNM classification (2002). The clinicopathological characteristics of all 220 patients with gastric cancer enrolled in this study are summarized in Table 1. The samples were carefully dissected from resected specimens by a pathologist and immediately snap-frozen in separate vials, using liquid nitrogen. These frozen specimens were stored at –80°C in a tumor bank before use. All patients had follow-up records for more than 5 years. The follow-up deadline was December 2010. Overall survival was defined as the time from surgery until death by cancer or the last clinical assessment.
Table 1 Clinicopathological features of all 220 patients with gastric cancer

<table>
<thead>
<tr>
<th>Features</th>
<th>Number of cases (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td></td>
</tr>
<tr>
<td>≤55</td>
<td>112 (50.91)</td>
</tr>
<tr>
<td>&gt;55</td>
<td>108 (49.09)</td>
</tr>
<tr>
<td>Sex</td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>160 (72.73)</td>
</tr>
<tr>
<td>Female</td>
<td>60 (27.27)</td>
</tr>
<tr>
<td>Tumor location</td>
<td></td>
</tr>
<tr>
<td>Cardia</td>
<td>30 (13.64)</td>
</tr>
<tr>
<td>Body</td>
<td>82 (37.27)</td>
</tr>
<tr>
<td>Antrum</td>
<td>108 (49.09)</td>
</tr>
<tr>
<td>Differentiation degree</td>
<td></td>
</tr>
<tr>
<td>Well differentiated</td>
<td>49 (22.27)</td>
</tr>
<tr>
<td>Moderately differentiated</td>
<td>58 (26.36)</td>
</tr>
<tr>
<td>Poorly differentiated</td>
<td>25 (11.36)</td>
</tr>
<tr>
<td>Depth of invasion</td>
<td></td>
</tr>
<tr>
<td>T1/T2</td>
<td>71 (32.27)</td>
</tr>
<tr>
<td>T3/T4</td>
<td>149 (67.73)</td>
</tr>
<tr>
<td>Lymph node metastasis</td>
<td></td>
</tr>
<tr>
<td>N0</td>
<td>42 (19.09)</td>
</tr>
<tr>
<td>N1</td>
<td>80 (36.36)</td>
</tr>
<tr>
<td>N2</td>
<td>68 (30.91)</td>
</tr>
<tr>
<td>N3</td>
<td>30 (13.64)</td>
</tr>
<tr>
<td>Distant metastasis</td>
<td></td>
</tr>
<tr>
<td>M0</td>
<td>190 (86.36)</td>
</tr>
<tr>
<td>M1</td>
<td>30 (13.64)</td>
</tr>
<tr>
<td>TNM stage</td>
<td></td>
</tr>
<tr>
<td>I</td>
<td>65 (29.55)</td>
</tr>
<tr>
<td>II</td>
<td>15 (6.82)</td>
</tr>
<tr>
<td>III</td>
<td>20 (9.09)</td>
</tr>
<tr>
<td>IV</td>
<td>120 (54.55)</td>
</tr>
</tbody>
</table>

RNA extraction and real-time quantitative PCR

miR-126 and CRK mRNA expression levels in 220 gastric cancer tissues and the matched normal gastric mucosa were detected by real-time quantitative PCR as described in our previous study.26 U6 and GAPDH were, respectively, used as internal controls for the detection of miR-126 and CRK mRNA expression. Specific primers were designed for the reverse transcription: the primer sequences for miR-126 were 5′-TCC AAT ATG ATT CC-3′, reverse 5′-TGG ACT CCA CGA CGT ACT CAG-3′; for CRK, forward 5′-ACG ATG GTG TAA TGG ACT CCA CGA CGT ACT CAG-3′, reverse 5′-TGG ACT CCA CGA CGT ACT CAG-3′; and for GAPDH, forward 5′-ACA TGT TTC AAT ATG ATT CC-3′, reverse 5′-TGG ACT CCA CGA CGT ACT CAG-3′. Each reaction was performed in triplicate, and the expression levels of miR-126 and CRK mRNA were both calculated as 2-ΔΔCt, where ΔCt = Ct (miR-126 or CRK mRNA) – Ct (U6 or GAPDH). In addition, the median values of miR-126 or CRK expression levels in gastric cancer tissues were, respectively, used as cutoff points to divide all 220 patients into miR-126-high/low groups or CRK-high/low groups.

Statistical analysis

SPSS version 12.0 for Windows software (SPSS Inc., Chicago, IL, USA) and SAS 9.1 software (SAS Institute Inc., Cary, NC, USA) were used for statistical analysis. Measurement data were analyzed using Student’s t-test, while categorial data were studied using the chi-square test or Fisher’s exact test. Correlations between miR-126 and CRK mRNA expression were calculated using Spearman’s correlation. Survival curves were estimated using the Kaplan–Meier method, and the log-rank test was used to calculate differences between the curves. Multivariate survival analyses were conducted by a Cox proportional hazards regression model to find the factors that affect the prognosis of gastric cancer. Differences were considered statistically significant when P was less than 0.05.

Results

miR-126 and CRK mRNA expression levels were, respectively, decreased and increased in human gastric cancer tissues

miR-126 expression levels in gastric cancer tissues were significantly decreased (cancer vs normal: 1.79±0.79 vs 3.90±1.17; P<0.001) (Figure 2A), while CRK mRNA expression levels in gastric cancer tissues were dramatically increased (cancer vs normal: 3.74±1.08 vs 1.50±0.54; P<0.001) (Figure 2B), compared with the matched normal gastric mucosa. According to our method of grouping, 34 in 220 (15.45%) cases had high expression of both miR-126 and CRK, 40 in 220 (18.18%) cases had low expression of both miR-126 and CRK, 68 in 220 (30.91%) cases had miR-126-high and CRK-low expression, and 78 in 220 (35.45%) cases had miR-126-low and CRK-high expression. More interestingly, the expression levels of miR-126 in gastric cancer tissues were significantly negatively correlated with those of CRK mRNA as determined by Spearman’s correlation (r=−0.412, P<0.001) (Figure 2C).
The associations between miR-126 and/or CRK expression levels and clinicopathological features of gastric cancer are summarized in Tables 2 and S1. The results revealed that low miR-126 expression and high CRK expression, alone or in combination, were all significantly associated with positive lymph node (P = 0.01, P = 0.01, and P = 0.005, respectively) and distant (P = 0.008, P = 0.008, and P = 0.001, respectively) metastases and advanced TNM stage (all P < 0.001) of patients with gastric cancer.

**Dysregulation of miR-126/CRK axis associates with aggressive progression in human gastric cancer**

The associations between miR-126 and/or CRK expression levels and clinicopathological features of gastric cancer are summarized in Tables 2 and S1. The results revealed that low miR-126 expression and high CRK expression, alone or in combination, were all significantly associated with positive lymph node (P = 0.01, P = 0.01, and P = 0.005, respectively) and distant (P = 0.008, P = 0.008, and P = 0.001, respectively) metastases and advanced TNM stage (all P < 0.001) of patients with gastric cancer.

**Dysregulation of miR-126/CRK axis predicts poor prognosis in patients with gastric cancer**

Kaplan–Meier plots of overall survival curves stratified by miR-126 or CRK expression are, respectively, shown in Figure 3A and B. A significant relationship was found between miR-126 expression and overall survival (P = 0.001, log-rank test). In contrast, the overall survival (P = 0.001, log-rank test) of gastric cancer patients with high CRK expression was significantly shorter than in those with low CRK expression. Moreover, the chi-square value by log-rank (Mantel–Cox) indicated a significant difference among different groups with regard to the combined expression status of miR-126/CRK (Figure 3C). The results by pairwise comparisons showed that a statistically significant difference of overall survival existed between miR-126-low/CRK-high patients and any of the other two groups (P < 0.001). In all three groups, miR-126-low/CRK-high patients had the worst prognosis.

A separate univariate analysis of the TNM stage IV group demonstrated that miR-126-low (P = 0.001), CRK-high (P = 0.001), and miR-126-low/CRK-high (P < 0.001) were all significantly associated with unfavorable overall survival (Figure 3D–F). In contrast, only combined miR-126/CRK expression was significantly associated with overall survival of patients in the TNM stage I–III group (P = 0.01) (Figure 3G–I).

Table 3 shows the multivariate analyses of factors related to patient prognosis. Factors with possible prognostic effects
in gastric cancer were analyzed by Cox regression analysis. The results revealed that lymph node metastases (P=0.02), distant metastases (P=0.02), TNM stage (P=0.01), miR-126 expression (P=0.01), CRK expression (P=0.01), and miR-126/CRK combined expression (P=0.001) were independent prognostic factors of patients with gastric cancer. However, age, sex, tumor differentiation, and depth of tumor invasion had no prognostic value.

A separate multivariate analysis of the TNM stage IV group demonstrated that miR-126 expression, CRK expression, and miR-126/CRK expression were all independent prognostic factors of patients with TNM stage IV gastric cancer (all P<0.05) (Table 4), but not for those with TNM stage I–III (all P>0.05) (data not shown).

### Discussion

Gastric cancer remains a major cause of morbidity and mortality worldwide, thus there is a clear need to search for more efficient molecular markers for diagnosis and prognosis in this disease. miRNAs are a recently discovered category of small RNA molecules that regulate gene expression posttranscriptionally. Growing evidence shows that miRNAs are aberrantly expressed in a variety of human cancers and crucial to tumorigenesis. We herein provide the evidence that miR-126 and CRK mRNA expression levels were, respectively, decreased and increased in gastric cancers and crucial to tumorigenesis. We found that low miR-126 and high CRK expression levels, alone or in combination, were all significantly associated with aggressive progression and patients’ poor prognosis in gastric cancer. More interestingly, the aberrant expression levels of miR-126 and CRK mRNA were both observed from early- to advanced-stage gastric cancer and were closely correlated with lymph node and distant metastases. These data imply that miR-126/CRK axis in gastric cancer may play an important role in the process
Figure 3 Overall survival curves for gastric cancer patients.

Notes: (A–C) Overall survival curves for two groups defined by low and high expression of miR-126 or CRK mRNA and for four groups defined by combined expression of miR-126 and CRK in gastric cancer. (D–F) Overall survival curves for two groups defined by low and high expression of miR-126 or CRK mRNA and for four groups defined by combined expression of miR-126 and CRK in gastric cancer with TNM stage IV. (G–I) Overall survival curves for two groups defined by low and high expression of miR-126 or CRK mRNA and for four groups defined by combined expression of miR-126 and CRK in gastric cancer with TNM stage I–III. “Dual expression” refers to patients with miR-126-low/CRK-low plus patients with miR-126-high/CRK-high.

Abbreviation: CRK, C10 oncogene homologue.

Table 3 Multivariate analyses of prognostic factors in gastric cancer

<table>
<thead>
<tr>
<th>Independent factors</th>
<th>Multivariate P-value</th>
<th>Hazard ratio</th>
<th>95% confidence interval</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (&lt;55 vs &gt;55 years)</td>
<td>0.23</td>
<td>1.26</td>
<td>0.73–2.20</td>
</tr>
<tr>
<td>Sex (male vs female)</td>
<td>0.20</td>
<td>1.35</td>
<td>0.77–2.35</td>
</tr>
<tr>
<td>Tumor location (cardia and body vs antrum)</td>
<td>0.18</td>
<td>1.68</td>
<td>0.89–3.82</td>
</tr>
<tr>
<td>Differentiation degree (well and moderately differentiated vs poorly differentiated)</td>
<td>0.26</td>
<td>1.18</td>
<td>0.48–2.95</td>
</tr>
<tr>
<td>Depth of invasion (T1/T2 vs T3/T4)</td>
<td>0.21</td>
<td>1.42</td>
<td>1.01–2.28</td>
</tr>
<tr>
<td>Lymph node metastasis (N0/N1 vs N2/N3)</td>
<td>0.02</td>
<td>4.17</td>
<td>1.03–18.92</td>
</tr>
<tr>
<td>Distant metastasis (M0 vs M1)</td>
<td>0.02</td>
<td>4.28</td>
<td>1.06–19.18</td>
</tr>
<tr>
<td>TNM stage (I–II vs III–IV)</td>
<td>0.01</td>
<td>4.76</td>
<td>1.09–19.63</td>
</tr>
<tr>
<td>miR-126 expression (low vs high)</td>
<td>0.01</td>
<td>4.28</td>
<td>1.01–16.32</td>
</tr>
<tr>
<td>CRK expression (low vs high)</td>
<td>0.01</td>
<td>4.79</td>
<td>1.10–20.26</td>
</tr>
<tr>
<td>miR-126/CRK expression (low/low, high/low, and high/high)</td>
<td>0.001</td>
<td>9.80</td>
<td>1.89–26.88</td>
</tr>
</tbody>
</table>

Abbreviation: CRK, C10 oncogene homologue.
Multivariate analyses of prognostic factors in gastric cancer with TNM stage IV

<table>
<thead>
<tr>
<th>Independent factors</th>
<th>Multivariate P-value</th>
<th>Hazard ratio</th>
<th>95% confidence interval</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (≤55 vs &gt;55 years)</td>
<td>0.18</td>
<td>1.68</td>
<td>0.69–3.22</td>
</tr>
<tr>
<td>Sex (male vs female)</td>
<td>0.17</td>
<td>1.62</td>
<td>0.81–3.88</td>
</tr>
<tr>
<td>Tumor location (cardia and body vs antrum)</td>
<td>0.20</td>
<td>2.06</td>
<td>0.82–4.32</td>
</tr>
<tr>
<td>Differentiation degree (well and moderately differentiated vs poorly differentiated)</td>
<td>0.23</td>
<td>2.18</td>
<td>0.88–4.60</td>
</tr>
<tr>
<td>Depth of invasion (T1/T2 vs T3/T4)</td>
<td>0.28</td>
<td>2.89</td>
<td>0.93–5.27</td>
</tr>
<tr>
<td>Lymph node metastasis (N0/N1 vs N2/N3)</td>
<td>0.001</td>
<td>6.32</td>
<td>2.66–20.98</td>
</tr>
<tr>
<td>Distant metastasis (M0 vs M1)</td>
<td>0.001</td>
<td>6.56</td>
<td>2.98–22.32</td>
</tr>
<tr>
<td>miR-126 expression (low vs high)</td>
<td>0.001</td>
<td>6.82</td>
<td>3.01–22.96</td>
</tr>
<tr>
<td>CRK expression (low vs high)</td>
<td>0.001</td>
<td>6.96</td>
<td>3.13–23.02</td>
</tr>
<tr>
<td>miR-126/CRK expression (low/high vs low/low, high/low, and high/high)</td>
<td>&lt;0.001</td>
<td>11.28</td>
<td>3.89–30.86</td>
</tr>
</tbody>
</table>

Abbreviation: CRK, CT10 oncogene homologue.

of tumor initiation and dissemination of cancer cells to distant organs.

miR-126, which is mapped within its host gene EGFL-7 and is highly expressed in vascular endothelial cells, has been reported to be a tumor suppressor in various human cancer types.\textsuperscript{27–32} For example, Jia et al\textsuperscript{27} found that restoration of miR-126 levels attenuated the invasive potential of bladder cancer cells through its ability to target ADAM9; Yang et al\textsuperscript{31} identified the tumor suppressive effect of miR-126 on oral squamous cell carcinoma in vitro; Sun et al\textsuperscript{31} indicated that miR-126 was able to inhibit laryngeal squamous cell carcinoma partly by suppressing Camssap1 expression which could induce microtubule formation and aggregation; and Guo et al\textsuperscript{29} noted loss of miR-126 expression in colon cancer cell lines when compared to normal human colon epithelia and revealed that miR-126 regulated PI3K signaling partly by targeting p85b. Similarly, miR-126 has been demonstrated to suppress tumor invasion and metastasis of gastric cancer via regulating many target genes, including CRK.\textsuperscript{20–23}

In the current study, we paid special attention to the clinical significance of miR-126/CRK axis in human gastric cancer. At first, we confirmed the aberrant expression of miR-126 and CRK mRNA in gastric cancer tissues. Consistently, miR-126 downregulation has been observed in various cancer types, including oral squamous cell cancer, breast cancer, non-small-cell lung cancer, prostate cancer, and renal cell carcinoma,\textsuperscript{27–32} and CRK overexpression has also been found in cancerous epithelial cells of breast, lung, oral, or head and neck origin, leading to the enhancement of epithelial-tomesenchymal transitions, characterized by the breakdown of adherens junctions, enhanced cell dispersal, and remodeling of cortical actin.\textsuperscript{33,34} In addition, the associations of miR-126 and/or CRK expression with clinicopathological features were also analyzed. Our data demonstrated that low miR-126 expression and high CRK expression, alone or in combination, were all significantly associated with positive metastasis and advanced tumor stage. According to the previous study of Li et al,\textsuperscript{24} miR-126 was significantly related with histologic differentiation, which was not in line with our data. The reason for this difference might be the heterogeneity of different patient cohorts. We further observed that miR-126 might be a favorable prognostic factor; in contrast, CRK might be considered an oncogene associated with poor prognosis in human gastric cancer.

Li et al\textsuperscript{16} previously identified a seven-miRNA signature (miR-10b, miR-21, miR-223, miR-338, let-7a, miR-30a-5p, miR-126) for overall survival and relapse-free survival of gastric cancer patients. However, the prognostic impact of miR-126 was larger than in the previous studies\textsuperscript{16} due to the heterogeneity of different patient cohorts. Moreover, an emerging body of evidence suggests that the aberrant expression of miR-126 and CRK correlates with prognosis in various other human cancers. For example, Donnem et al\textsuperscript{30} identified miR-126 as a strong and independent negative prognostic factor in non-small-cell lung cancer, and its prognostic impact might be related primarily to histology and nodal status; Liu et al\textsuperscript{32} indicated that miR-126 was an independent prognostic factor for overall survival, suggesting its clinical significance as a prognostic predictor in colorectal cancer patients. More importantly, in the current study, patients with miR-126 downregulation in combination with CRK upregulation had a worse overall survival than all of the other patients, and the prognostic potential of combined miR-126/CRK expression was better than the two markers alone.

Conclusion
The findings of the current study suggest that miR-126 and CRK combined expression may serve as an independent predictor of overall survival in patients with advanced gastric cancer.
cancer. Detection of their combined expression might be particularly helpful for surveillance of disease progression and treatment stratification.

Disclosure
The authors report no conflicts of interest in this work.

References
### Supplementary material

**Table S1** Association of miR-126-high, CRK-low, and miR-126-high/CRK-low expression with the clinicopathological features of gastric cancer

<table>
<thead>
<tr>
<th>Features</th>
<th>Number of cases</th>
<th>miR-126-high, n (%)</th>
<th>P-value</th>
<th>CRK-low, n (%)</th>
<th>P-value</th>
<th>miR-126-high/CRK-low, n (%)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤ 55</td>
<td>112</td>
<td>52 (46.43)</td>
<td>0.26</td>
<td>56 (50.00)</td>
<td>0.29</td>
<td>31 (27.68)</td>
<td>0.20</td>
</tr>
<tr>
<td>&gt; 55</td>
<td>108</td>
<td>50 (46.30)</td>
<td></td>
<td>52 (48.15)</td>
<td></td>
<td>37 (34.26)</td>
<td></td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>160</td>
<td>74 (46.25)</td>
<td>0.26</td>
<td>80 (50.00)</td>
<td>0.22</td>
<td>53 (33.13)</td>
<td>0.20</td>
</tr>
<tr>
<td>Female</td>
<td>60</td>
<td>28 (46.67)</td>
<td></td>
<td>28 (46.67)</td>
<td></td>
<td>15 (25.00)</td>
<td></td>
</tr>
<tr>
<td>Tumor location</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cardia</td>
<td>30</td>
<td>14 (46.67)</td>
<td>0.16</td>
<td>15 (50.00)</td>
<td>0.19</td>
<td>8 (26.67)</td>
<td>0.28</td>
</tr>
<tr>
<td>Body</td>
<td>82</td>
<td>32 (39.02)</td>
<td></td>
<td>37 (45.12)</td>
<td></td>
<td>26 (31.71)</td>
<td></td>
</tr>
<tr>
<td>Antrum</td>
<td>108</td>
<td>56 (51.85)</td>
<td></td>
<td>56 (51.85)</td>
<td></td>
<td>34 (31.48)</td>
<td></td>
</tr>
<tr>
<td>Differentiation degree</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Well differentiated</td>
<td>40</td>
<td>16 (40.00)</td>
<td>0.21</td>
<td>20 (50.00)</td>
<td>0.33</td>
<td>14 (35.00)</td>
<td>0.21</td>
</tr>
<tr>
<td>Moderately differentiated</td>
<td>58</td>
<td>26 (44.83)</td>
<td></td>
<td>28 (48.28)</td>
<td></td>
<td>18 (31.03)</td>
<td></td>
</tr>
<tr>
<td>Poorly differentiated</td>
<td>122</td>
<td>60 (49.18)</td>
<td></td>
<td>60 (49.18)</td>
<td></td>
<td>36 (29.51)</td>
<td></td>
</tr>
<tr>
<td>Depth of invasion</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>T1/T2</td>
<td>71</td>
<td>29 (40.85)</td>
<td>0.12</td>
<td>29 (40.85)</td>
<td>0.09</td>
<td>23 (32.39)</td>
<td>0.21</td>
</tr>
<tr>
<td>T3/T4</td>
<td>149</td>
<td>73 (48.99)</td>
<td></td>
<td>79 (53.02)</td>
<td></td>
<td>45 (30.20)</td>
<td></td>
</tr>
<tr>
<td>Lymph node metastasis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>N0</td>
<td>42</td>
<td>36 (85.71)</td>
<td>0.01</td>
<td>36 (85.71)</td>
<td>0.01</td>
<td>33 (78.57)</td>
<td>0.008</td>
</tr>
<tr>
<td>N1</td>
<td>80</td>
<td>50 (62.50)</td>
<td></td>
<td>52 (65.00)</td>
<td></td>
<td>23 (28.75)</td>
<td></td>
</tr>
<tr>
<td>N2</td>
<td>68</td>
<td>15 (22.06)</td>
<td></td>
<td>18 (26.47)</td>
<td></td>
<td>10 (14.71)</td>
<td></td>
</tr>
<tr>
<td>N3</td>
<td>30</td>
<td>1 (3.33)</td>
<td></td>
<td>2 (6.67)</td>
<td></td>
<td>2 (6.67)</td>
<td></td>
</tr>
<tr>
<td>Distant metastasis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>M0</td>
<td>190</td>
<td>102 (53.68)</td>
<td>0.008</td>
<td>108 (56.84)</td>
<td>0.008</td>
<td>63 (33.16)</td>
<td>0.03</td>
</tr>
<tr>
<td>M1</td>
<td>30</td>
<td>0 (0.00)</td>
<td></td>
<td>0 (0.00)</td>
<td></td>
<td>5 (16.67)</td>
<td></td>
</tr>
<tr>
<td>TNM stage</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I</td>
<td>65</td>
<td>65 (100.00)</td>
<td>&lt;0.001</td>
<td>65 (100.00)</td>
<td>&lt;0.001</td>
<td>50 (76.92)</td>
<td>0.01</td>
</tr>
<tr>
<td>II</td>
<td>15</td>
<td>9 (60.00)</td>
<td></td>
<td>13 (86.67)</td>
<td></td>
<td>8 (53.33)</td>
<td></td>
</tr>
<tr>
<td>III</td>
<td>20</td>
<td>8 (40.00)</td>
<td></td>
<td>8 (40.00)</td>
<td></td>
<td>5 (25.00)</td>
<td></td>
</tr>
<tr>
<td>IV</td>
<td>120</td>
<td>20 (16.67)</td>
<td></td>
<td>22 (18.33)</td>
<td></td>
<td>5 (4.17)</td>
<td></td>
</tr>
</tbody>
</table>

**Abbreviation:** CRK, CT10 oncogene homologue.